HIV-infected patients who received a broadly neutralizing antibody had delayed virus rebound, compared with historical controls, when antiretroviral therapy was stopped.
Several broadly neutralizing antibodies (bNAbs) against HIV are entering clinical trials aimed at prevention or treatment of HIV. To assess the effect of 3BNC117 (an antibody against the HIV envelope CD4 binding site) on time to virus rebound once antiretroviral therapy (ART) is stopped, investigators administered multiple infusions of the antibody to 13 patients on suppressive ART and then interrupted ART 2 days after the first infusion.
Virus rebound occurred 5 to 9 weeks (mean, 6.7 weeks) after ART was stopped in participants who received two 3BNC117 doses 3 weeks apart, and 3 to 19 weeks (mean, 9.9 weeks) after ART was stopped in those who received four doses at 2-week intervals — both significantly later than the mean 2.6 weeks to rebou…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)